TY - T1的系统性硬化进展的预测因子间质性肺病患者JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02026 -2019欧元六世- 55 - 5 SP - 1902026 AU Distler奥利弗盟——Assassi Shervin盟——Cottin文森特盟——Cutolo Maurizio盟——Danoff Sonye k . AU -丹顿,Christopher P. AU - Distler, Jörg H.W. AU - Hoffmann-Vold, Anna-Maria AU - Johnson, Sindhu R. AU - Müller Ladner, Ulf AU - Smith, Vanessa AU - Volkmann, Elizabeth R. AU - Maher，Toby M. Y1 - 2020/05/01 UR - //www.qdcxjkg.com/content/55/5/1902026.abstract N2 -系统性硬化症(Systemic sclerosis, SSc)是一种影响包括肺在内的多器官系统的系统性自身免疫性疾病。间质性肺病(ILD)是SSc患者死亡的主要原因。目前尚无有效的生物标志物预测SSc-ILD的发生，尽管抗拓扑异构酶I的自身抗体和一些炎症标志物是需要进一步评估的候选生物标志物。胸部听诊、气短和肺功能检测是重要的诊断工具，但对早期肺间质性肺病缺乏敏感性。因此，基线筛查高分辨率计算机断层扫描(HRCT)是必要的，以确认SSc-ILD诊断。一旦诊断为SSc-ILD，患者的临床病程变化多端且难以预测，尽管某些患者特征和生物标志物与疾病进展相关。监测SSc-ILD患者疾病进展的迹象是重要的，尽管对于使用何种诊断工具或监测的频率没有共识。在这篇文章中，我们回顾了用于定义和预测SSc-ILD疾病进展的方法。There is no valid definition of SSc-ILD disease progression, but we suggest that either a decline in forced vital capacity (FVC) from baseline of ≥10%, or a decline in FVC of 5–9% in association with a decline in diffusing capacity of the lung for carbon monoxide of ≥15% represents progression. An increase in the radiographic extent of ILD on HRCT imaging would also signify progression. A time period of 1–2 years is generally used for this definition, but a decline over a longer time period may also reflect clinically relevant disease progression.Lung function tests and chest imaging help predict who has SSc-associated ILD and whether it will progress. In the absence of standardised methods for doctors, we recommend a strategy that combines both lung function tests and chest imaging. http://bit.ly/2uK9ZD2 ER -